المؤلفون: Huijie Jiang, Sheng Zhao, Hao Jiang, Xu Zeng, Ruoshui Zheng, Ran Sun, Yanmei Dai

المصدر: Translational Oncology
Translational Oncology, Vol 14, Iss 12, Pp 101238-(2021)

مصطلحات موضوعية: Cancer Research, Survival, Hepatocellular carcinoma, PD-L1, programmed death ligand 1, urologic and male genital diseases, Gastroenterology, AEs, adverse events, law.invention, ORR, objective response rate, PR, partial response, Randomized controlled trial, DEB-TACE, trans-arterial chemoembolization with drug-eluting beads, law, Medicine, heterocyclic compounds, RCT, randomized controlled trial, RR, risk ratio, RC254-282, Original Research, BCLC, Barcelona clinic liver cancer, HFSR, hand-foot skin reaction, Hazard ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ECOG, Eastern cooperative oncology group, Sorafenib, VEGF, vascular endothelial growth factor, female genital diseases and pregnancy complications, PFS, progression-free survival, Oncology, mRECIST, modified RECIST, Meta-analysis, HCV, hepatitis C virus, TTUP, time to untreatable progression, CR, complete response, Safety, medicine.drug, DCR, disease control rate, medicine.medical_specialty, PD, progressive disease, Combination therapy, Subgroup analysis, OS, overall survival, Internal medicine, RECIST, response evaluation in solid tumors, neoplasms, business.industry, Trans-arterial chemoembolization, SD, stable disease, TTP, time to progression, HR, hazard ratio, Confidence interval, digestive system diseases, HBV, hepatitis B virus, CI, confidence intervals, Relative risk, business, HCC, hepatocellular carcinoma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b81951a380a5cfd57f90d14e20dcc2
https://pubmed.ncbi.nlm.nih.gov/34628285